Medicine:Celacade
Celacade was a non-drug, device-based treatment also known as Immune Modulation Therapy (IMT), developed by the Canadian-based biotherapeutics company Vasogen, Inc. for chronic heart failure and peripheral artery disease.[1][2] Blood was piped through the device, where it was exposed to heat, ultraviolet light, and ozone, in the hope that this oxidative stress would trigger an anti-inflammatory immunomodulation response.[3][4][5]
Despite some promising early results and one positive result in subgroup analysis, the technique usually did not produce the hoped-for clinically significant results.[3][5]
Research history
At the World Congress of Cardiology in September 2006 the Advanced Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy (ACCLAIM) a phase III randomized, double-blind, placebo-controlled clinical trial involving some 2408 patients in 7 countries with left ventricular ejection fraction of 30% or less, reported that only one subgroup – patients with a previous cardiovascular event – benefited from the treatment.[3] These people were 39% less likely to die or be hospitalized due to a heart attack or stroke and tended to have improved quality of life.[6][3]
Marketing approval
Vasogen in collaboration with Grupo Ferrer Internacional has regulatory approval to market Celacade as a medical device for the treatment of chronic heart failure in the European Union and Latin America.[7]
References
- ↑ Visioli F (September 2001). "VasoCare. Vasogen". Curr Opin Investig Drugs 2 (9): 1247–9. PMID 11717811.
- ↑ "Immune modulation therapy-peripheral vascular disease--Vasogen (VasoCare)". Drugs in R&D 3 (5): 358–60. 2002. doi:10.2165/00126839-200203050-00013. PMID 12455159.
- ↑ 3.0 3.1 3.2 3.3 Kumar, Soumitra (2018-03-31) (in en). The Protocol Book for Intensive Care. JP Medical Ltd. pp. 165–166. ISBN 978-93-5270-305-0. https://books.google.com/books?id=boJXDwAAQBAJ&q=celacade&pg=PA165.
- ↑ "Effect of combined heat, ozonation and ultraviolet irradiation (VasoCare) on heat shock protein expression by peripheral blood leukocyte populations". J. Biol. Regul. Homeost. Agents 11 (3): 104–10. 1997. PMID 9498159.
- ↑ 5.0 5.1 Tousoulis, Dimitris; Stefanadis, Christodoulos (2013-07-29) (in en). Biomarkers in Cardiovascular Diseases. CRC Press. pp. 380. ISBN 978-1-4665-8714-4. https://books.google.com/books?id=-R4bAAAAQBAJ&q=celacade&pg=PA380.
- ↑ "A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: the ACCLAIM trial rationale and design". Can J Cardiol 23 (5): 369–76. April 2007. doi:10.1016/s0828-282x(07)70770-5. PMID 17440642.
- ↑ "Vasogen and Grupo Ferrer Form Collaboration to Commercialize Celacade in the European Union". Vasogen Inc. April 18, 2007. http://www.vasogen.com/sec/pr_1176892968.
External links
 |  |
